Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Google ScholarÂ
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
Google ScholarÂ
Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41:4267–78.
Google ScholarÂ
Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42:354–73.
Google ScholarÂ
Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.
Google ScholarÂ
Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov. 2016;15:699–718.
Google ScholarÂ
Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11:792–804.
Google ScholarÂ
Hatakeyama S. TRIM family proteins: roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 2017;42:297–311.
Google ScholarÂ
Endo H, Ikeda K, Urano T, Horie-Inoue K, Inoue S. Terf/TRIM17 stimulates degradation of kinetochore protein ZWINT and regulates cell proliferation. J Biochem. 2012;151:139–44.
Google ScholarÂ
Xiao S, Yu J, Yuan X, Chen Q. Identification of a tripartite motif family gene signature for predicting the prognosis of patients with glioma. Am J Transl Res. 2022;14:1535–50.
Google ScholarÂ
Liu W, Zheng D, Huang X, Wei Z, Wei Z, Guo W. TRIM17 promotes the progression of osteosarcoma by regulating PDK1 m6A modification-mediated AKT/mTOR pathway activation through ubiquitination of FTO. Cell Death Dis. 2025;16:767.
Google ScholarÂ
Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2019;26:902–17.
Google ScholarÂ
Zhong T, Zhang J, Liu X, Li H. TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer. Cell Oncol. 2023;46:1493–507.
Google ScholarÂ
Shen J, Yang H, Qiao X, Chen Y, Zheng L, Lin J, et al. The E3 ubiquitin ligase TRIM17 promotes gastric cancer survival and progression via controlling BAX stability and antagonizing apoptosis. Cell Death Differ. 2023;30:2322–35.
Google ScholarÂ
Liu P, Zhao L, Zitvogel L, Kepp O, Kroemer G. The BCL2 inhibitor venetoclax mediates anticancer effects through dendritic cell activation. Cell Death Differ. 2023;30:2447–51.
Google ScholarÂ
Li Z, Ning K, Zhao D, Zhou Z, Zhao J, Long X, et al. Targeting the metabolic enzyme PGAM2 overcomes enzalutamide resistance in castration-resistant prostate cancer by inhibiting BCL2 signaling. Cancer Res. 2023;83:3753–66.
Google ScholarÂ
Wei H, Wang H, Wang G, Qu L, Jiang L, Dai S, et al. Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nat Commun. 2023;14:4300.
Google ScholarÂ
Jin JO, Lee GD, Nam SH, Lee TH, Kang DH, Yun JK, et al. Sequential ubiquitination of p53 by TRIM28, RLIM, and MDM2 in lung tumorigenesis. Cell Death Differ. 2021;28:1790–803.
Google ScholarÂ
Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, et al. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023;14:6269.
Google ScholarÂ
Basu-Shrivastava M, Kozoriz A, Desagher S, Lassot I. To ubiquitinate or not to ubiquitinate: TRIM17 in cell life and death. Cells. 2021; 10:1235.
Magiera MM, Mora S, Mojsa B, Robbins I, Lassot I, Desagher S. Trim17-mediated ubiquitination and degradation of Mcl-1 initiate apoptosis in neurons. Cell Death Differ. 2013;20:281–92.
Google ScholarÂ
Zheng S, Hong Z, Tan Y, Wang Y, Li J, Zhang Z, et al. MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway. Cell Commun Signal. 2024;22:517.
Google ScholarÂ
Lassot I, Robbins I, Kristiansen M, Rahmeh R, Jaudon F, Magiera MM, et al. Trim17, a novel E3 ubiquitin-ligase, initiates neuronal apoptosis. Cell Death Differ. 2010;17:1928–41.
Google ScholarÂ
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, et al. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021;12:6896.
Google ScholarÂ
Liang Y, Jeganathan S, Marastoni S, Sharp A, Figueiredo I, Marcellus R, et al. Emergence of enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies. Clin Cancer Res. 2021;27:2340–51.
Google ScholarÂ
Lin CH, Chen TJ, Chen SS, Hsiao PC, Yang RC. Activation of Trim17 by PPARγ is involved in di(2-ethylhexyl) phthalate (DEHP)-induced apoptosis on Neuro-2a cells. Toxicol Lett. 2011;206:245–51.
Google ScholarÂ
Pilling AB, Hwang C. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Prostate. 2019;79:1347–59.
Google ScholarÂ
Cao J, Yang M, Guo D, Tao Z, Hu X. Emerging roles of tripartite motif family proteins (TRIMs) in breast cancer. Cancer Med. 2024;13:e7472.
Google ScholarÂ
Pearson A, Koprivica M, Eisenbaum M, Ortiz C, Browning M, Vincennie T, et al. PPARγ activation ameliorates cognitive impairment and chronic microglial activation in the aftermath of r-mTBI. J Neuroinflammation. 2024;21:194.
Google ScholarÂ
Beshiri M, Agarwal S, Yin JJ, Kelly K. Prostate organoids: emerging experimental tools for translational research. J Clin Investig. 2023; 133:e169616.
Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23:87–98.
Google ScholarÂ
Qiu X, Hill A, Packer J, Lin D, Ma YA, Trapnell C. Single-cell mRNA quantification and differential analysis with Census. Nat Methods. 2017;14:309–15.
Google ScholarÂ
Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, et al. Preclinical study using Malat1 small interfering RNA and androgen receptor splicing variant 7 degradation enhancer ASC-J9(®) to suppress enzalutamide-resistant prostate cancer progression. Eur Urol. 2017;72:835–44.
Google ScholarÂ
